{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:13:29Z","timestamp":1768000409713,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Center - Portuguese Oncology Institute of Porto","award":["Grant PI 74-CI-IPOP-19-2015"],"award-info":[{"award-number":["Grant PI 74-CI-IPOP-19-2015"]}]},{"name":"N\u00facleo Regional da Madeira da Liga Portuguesa Contra o Cancro & Di\u00e1rio de Not\u00edcias","award":["2016"],"award-info":[{"award-number":["2016"]}]},{"name":"Research Center - Portuguese Oncology Institute of Porto","award":["CI-IPOP-BI-GEBC2018\/UID\/DTP\/00776\/POCI-01-0145-FEDER-006868"],"award-info":[{"award-number":["CI-IPOP-BI-GEBC2018\/UID\/DTP\/00776\/POCI-01-0145-FEDER-006868"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13148-018-0564-2","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T09:49:55Z","timestamp":1540806595000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients"],"prefix":"10.1186","volume":"10","author":[{"given":"Catarina","family":"Moreira-Barbosa","sequence":"first","affiliation":[]},{"given":"Daniela","family":"Barros-Silva","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Costa-Pinheiro","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Torres-Ferreira","sequence":"additional","affiliation":[]},{"given":"Vera","family":"Const\u00e2ncio","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Freitas","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Antunes","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,10,29]]},"reference":[{"issue":"6","key":"564_CR1","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.eururo.2012.02.054","volume":"61","author":"MM Center","year":"2012","unstructured":"Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079\u201392.","journal-title":"Eur Urol"},{"issue":"18","key":"564_CR2","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1101\/gad.1965810","volume":"24","author":"MM Shen","year":"2010","unstructured":"Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010;24(18):1967\u20132000.","journal-title":"Genes Dev"},{"issue":"1","key":"564_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrurol.2012.225","volume":"10","author":"MJ Roobol","year":"2013","unstructured":"Roobol MJ, Carlsson SV. Risk stratification in prostate cancer screening. Nat Rev Urol. 2013;10(1):38\u201348.","journal-title":"Nat Rev Urol"},{"issue":"10013","key":"564_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","volume":"387","author":"G Attard","year":"2016","unstructured":"Attard G, Parker C, Eeles RA, Schr\u00f6der F, Tomlins SA, Tannock I, Drake CG, De Bono JS. Prostate cancer. Lancet. 2016;387(10013):70\u201382.","journal-title":"Lancet"},{"issue":"2","key":"564_CR5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.canlet.2011.12.026","volume":"342","author":"C Jer\u00f3nimo","year":"2014","unstructured":"Jer\u00f3nimo C, Henrique R. Epigenetic biomarkers in urological tumors: a systematic review. Cancer Lett. 2014;342(2):264\u201374.","journal-title":"Cancer Lett"},{"key":"564_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsbmb.2016.04.009","volume":"166","author":"Charles E. Massie","year":"2017","unstructured":"Massie CE, Mills IG, Lynch AG. The importance of DNA methylation in prostate cancer development. J Steroid Biochem Mol Biol. 2017;166:1\u201315.","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"issue":"1","key":"564_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s12967-016-1014-6","volume":"14","author":"G Gurioli","year":"2016","unstructured":"Gurioli G, Salvi S, Martignano F, Foca F, Gunelli R, Costantini M, Cicchetti G, Giorgi U, Sbarba PD, Calistri D. Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach. J Transl Med. 2016;14(1):249.","journal-title":"J Transl Med"},{"key":"564_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.4103\/1008-682X.179859","volume":"18","author":"S Yegnasubramanian","year":"2016","unstructured":"Yegnasubramanian S. Prostate cancer epigenetics and its clinical implications. Asian J Androl. 2016;18:549.","journal-title":"Asian J Androl"},{"issue":"3","key":"564_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ejca.2008.12.008","volume":"45","author":"M Duffy","year":"2009","unstructured":"Duffy M, Napieralski R, Martens J, Span P, Spyratos F, Sweep F, Brunner N, Foekens J, Schmitt M. Methylated genes as new cancer biomarkers. Eur J Cancer. 2009;45(3):335\u201346.","journal-title":"Eur J Cancer"},{"issue":"5","key":"564_CR10","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.juro.2011.06.052","volume":"186","author":"J Baden","year":"2011","unstructured":"Baden J, Adams S, Astacio T, Jones J, Markiewicz J, Painter J, Trust C, Wang Y, Green G. Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng\/ml using an investigational prostate cancer methylation assay. J Urol. 2011;186(5):2101\u20136.","journal-title":"J Urol"},{"issue":"1","key":"564_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-017-0604-0","volume":"16","author":"J Torres-Ferreira","year":"2017","unstructured":"Torres-Ferreira J, Ramalho-Carvalho J, Gomez A, Menezes FD, Freitas R, Oliveira J, Antunes L, Bento MJ, Esteller M, Henrique R. MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b\/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors. Mol Cancer. 2017;16(1):26.","journal-title":"Mol Cancer"},{"issue":"11","key":"564_CR12","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1158\/1078-0432.CCR-04-2446","volume":"11","author":"PJ Bastian","year":"2005","unstructured":"Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res. 2005;11(11):4037\u201343.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"564_CR13","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-07-1042","volume":"13","author":"R Henrique","year":"2007","unstructured":"Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, Costa VL, Pinto M, Oliveira J, Teixeira MR, Sidransky D. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res. 2007;13(20):6122\u20139.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"564_CR14","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1373\/clinchem.2007.094912","volume":"54","author":"T Vener","year":"2008","unstructured":"Vener T, Derecho C, Baden J, Wang H, Rajpurohit Y, Skelton J, Mehrotra J, Varde S, Chowdary D, Stallings W. Development of a multiplexed urine assay for prostate cancer diagnosis. Clin Chem. 2008;54(5):874\u201382.","journal-title":"Clin Chem"},{"issue":"3","key":"564_CR15","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.juro.2009.05.003","volume":"182","author":"J Baden","year":"2009","unstructured":"Baden J, Green G, Painter J, Curtin K, Markiewicz J, Jones J, Astacio T, Canning S, Quijano J, Guinto W. Multicenter evaluation of an investigational prostate cancer methylation assay. J Urol. 2009;182(3):1186\u201393.","journal-title":"J Urol"},{"issue":"1","key":"564_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13000-016-0478-2","volume":"11","author":"J Gordetsky","year":"2016","unstructured":"Gordetsky J, Epstein J. Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagn Pathol. 2016;11(1):1.","journal-title":"Diagn Pathol"},{"issue":"12","key":"564_CR17","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/jnci\/djp122","volume":"101","author":"MR Cooperberg","year":"2009","unstructured":"Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009;101(12):878\u201387.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"564_CR18","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz S, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969\u201374.","journal-title":"JAMA"},{"issue":"10","key":"564_CR19","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1002\/cncr.22262","volume":"107","author":"MR Cooperberg","year":"2006","unstructured":"Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC, Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll PR. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer. 2006;107(10):2384\u201391.","journal-title":"Cancer"},{"issue":"5","key":"564_CR20","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359\u201386.","journal-title":"Int J Cancer"},{"issue":"127","key":"564_CR21","doi-asserted-by":"publisher","first-page":"127rv123","DOI":"10.1126\/scitranslmed.3003180","volume":"4","author":"JR Prensner","year":"2012","unstructured":"Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med. 2012;4(127):127rv123.","journal-title":"Sci Transl Med"},{"key":"564_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/B978-0-12-801899-6.00014-0","volume-title":"Epigenetic Biomarkers and Diagnostics. Edn","author":"J Ramalho-Carvalho","year":"2016","unstructured":"Ramalho-Carvalho J, Henrique R, Jer\u00f3nimo C. Chapter 14 - DNA methylation alterations as biomarkers for prostate cancer A2 - Garc\u00eda-Gim\u00e9nez, Jos\u00e9 Luis. In: Epigenetic Biomarkers and Diagnostics. Edn. Boston: Academic Press; 2016. p. 275\u201396."},{"issue":"4","key":"564_CR23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1586\/14737159.2015.1019477","volume":"15","author":"J Ellinger","year":"2015","unstructured":"Ellinger J, M\u00fcller SC, Dietrich D. Epigenetic biomarkers in the blood of patients with urological malignancies. Expert Rev Mol Diagn. 2015;15(4):505\u201316.","journal-title":"Expert Rev Mol Diagn"},{"key":"564_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.canlet.2016.10.028","volume":"385","author":"J Ramalho-Carvalho","year":"2017","unstructured":"Ramalho-Carvalho J, Martins JB, Cekaite L, Sveen A, Torres-Ferreira J, Graca I, Costa-Pinheiro P, Eilertsen IA, Antunes L, Oliveira J, et al. Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. Cancer Lett. 2017;385:150\u20139.","journal-title":"Cancer Lett"},{"issue":"1","key":"564_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13045-017-0415-1","volume":"10","author":"J Ramalho-Carvalho","year":"2017","unstructured":"Ramalho-Carvalho J, Graca I, Gomez A, Oliveira J, Henrique R, Esteller M, Jeronimo C. Downregulation of miR-130b~301b cluster is mediated by aberrant promoter methylation and impairs cellular senescence in prostate cancer. J Hematol Oncol. 2017;10(1):43.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"564_CR26","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.juro.2014.04.013","volume":"192","author":"AW Partin","year":"2014","unstructured":"Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, Rieger-Christ K, Jones JS, Magi-Galluzzi C, Mangold LA, et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol. 2014;192(4):1081\u20137.","journal-title":"J Urol"},{"issue":"3","key":"564_CR27","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.juro.2012.08.219","volume":"189","author":"GD Stewart","year":"2013","unstructured":"Stewart GD, Van Neste L, Delvenne P, Delr\u00e9e P, Delga A, McNeill SA, O'Donnell M, Clark J, Van Criekinge W, Bigley J. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol. 2013;189(3):1110\u20136.","journal-title":"J Urol"},{"issue":"12","key":"564_CR28","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/pros.23191","volume":"76","author":"L Van Neste","year":"2016","unstructured":"Van Neste L, Partin AW, Stewart GD, Epstein JI, Harrison DJ, Van Criekinge W. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. Prostate. 2016;76(12):1078\u201387.","journal-title":"Prostate"},{"issue":"6","key":"564_CR29","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/S0090-4295(02)01949-0","volume":"60","author":"C Jernimo","year":"2002","unstructured":"Jernimo C, Usadel H, Henrique R, Silva C, Oliveira J, Lopes C, Sidransky D. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology. 2002;60(6):1131\u20135.","journal-title":"Urology"},{"issue":"27","key":"564_CR30","doi-asserted-by":"publisher","first-page":"6569","DOI":"10.1200\/JCO.2005.07.009","volume":"23","author":"MO Hoque","year":"2005","unstructured":"Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W, Westra WH, Sidransky D. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol. 2005;23(27):6569\u201375.","journal-title":"J Clin Oncol"},{"issue":"6","key":"564_CR31","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1158\/1078-0432.CCR-06-2467","volume":"13","author":"M Roupret","year":"2007","unstructured":"Roupret M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, Ricci S, Lacave R, Cancel-Tassin G, de la Taille A, et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res. 2007;13(6):1720\u20135.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"564_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3109\/10408363.2014.914888","volume":"51","author":"B Ralla","year":"2014","unstructured":"Ralla B, Stephan C, Meller S, Dietrich D, Kristiansen G, Jung K. Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. Crit Rev Clin Lab Sci. 2014;51(4):200\u201331.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"Suppl 2","key":"564_CR33","first-page":"15","volume":"8","author":"P-O Gaudreau","year":"2016","unstructured":"Gaudreau P-O, Stagg J, Souli\u00e8res D, Saad F. The present and future of biomarkers in prostate cancer: proteomics, genomics, and immunology advancements. Biomark Cancer. 2016;8(Suppl 2):15.","journal-title":"Biomark Cancer"},{"issue":"3","key":"564_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/CCO.0000000000000065","volume":"26","author":"DA Sartori","year":"2014","unstructured":"Sartori DA, Chan DW. Biomarkers in prostate cancer: what\u2019s new? Curr Opin Oncol. 2014;26(3):259.","journal-title":"Curr Opin Oncol"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-018-0564-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13148-018-0564-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-018-0564-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T20:11:16Z","timestamp":1572293476000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-018-0564-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,29]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["564"],"URL":"https:\/\/doi.org\/10.1186\/s13148-018-0564-2","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,29]]},"assertion":[{"value":"6 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the institutional review board (Comiss\u00e3o de \u00c9tica para a Sa\u00fade \u2013 CES 120\/2015) of the Portuguese Oncology Institute of Porto, Portugal. All patients and asymptomatic donors enrolled had signed an informed consent (Tables\u00a0 and ).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"132"}}